| National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working … MH Jagasia, HT Greinix, M Arora, KM Williams, D Wolff, EW Cowen, ... Biology of Blood and Marrow Transplantation 21 (3), 389-401. e1, 2015 | 2277 | 2015 |
| Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) E Basch, BB Reeve, SA Mitchell, SB Clauser, LM Minasian, AC Dueck, ... Journal of the National Cancer Institute 106 (9), dju244, 2014 | 806 | 2014 |
| Validity and reliability of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) AC Dueck, TR Mendoza, SA Mitchell, BB Reeve, KM Castro, LJ Rogak, ... JAMA oncology 1 (8), 1051-1059, 2015 | 671 | 2015 |
| Guidelines for inclusion of patient-reported outcomes in clinical trial protocols: the SPIRIT-PRO extension M Calvert, D Kyte, R Mercieca-Bebber, A Slade, AW Chan, MT King, ... Jama 319 (5), 483-494, 2018 | 615 | 2018 |
| Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic … SZ Pavletic, P Martin, SJ Lee, S Mitchell, D Jacobsohn, EW Cowen, ... Biology of Blood and Marrow Transplantation 12 (3), 252-266, 2006 | 445 | 2006 |
| Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in … D Couriel, PA Carpenter, C Cutler, J Bolaños-Meade, NS Treister, ... Biology of Blood and Marrow Transplantation 12 (4), 375-396, 2006 | 384 | 2006 |
| Measuring therapeutic response in chronic graft-versus-host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic … SJ Lee, D Wolff, C Kitko, J Koreth, Y Inamoto, M Jagasia, J Pidala, ... Biology of Blood and Marrow Transplantation 21 (6), 984-999, 2015 | 333 | 2015 |
| A literature synthesis of symptom prevalence and severity in persons receiving active cancer treatment CM Reilly, DW Bruner, SA Mitchell, LM Minasian, E Basch, AC Dueck, ... Supportive Care in Cancer 21, 1525-1550, 2013 | 299 | 2013 |
| Recommended patient-reported core set of symptoms to measure in adult cancer treatment trials BB Reeve, SA Mitchell, AC Dueck, E Basch, D Cella, CM Reilly, ... JNCI: Journal of the National Cancer Institute 106 (7), dju129, 2014 | 293 | 2014 |
| Implementing evidence‐based practice: effectiveness of a structured multifaceted mentorship programme GR Wallen, SA Mitchell, B Melnyk, E Fineout‐Overholt, C Miller‐Davis, ... Journal of advanced nursing 66 (12), 2761-2771, 2010 | 292 | 2010 |
| Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute’s Patient-Reported Outcomes Version of the Common … PG Kluetz, DT Chingos, EM Basch, SA Mitchell American Society of Clinical Oncology Educational Book 36, 67-73, 2016 | 263 | 2016 |
| Putting evidence into practice: evidence-based interventions for fatigue during and following cancer and its treatment SA Mitchell Number 1/February 2007 11 (1), 99-113, 2007 | 253 | 2007 |
| The symptom experience in the first 100 days following allogeneic hematopoietic stem cell transplantation (HSCT) MF Bevans, SA Mitchell, S Marden Supportive care in cancer 16, 1243-1254, 2008 | 237 | 2008 |
| Cancer-related fatigue: state of the science SA Mitchell PM&R 2 (5), 364-383, 2010 | 209 | 2010 |
| Screening, evaluation, and management of cancer‐related fatigue: Ready for implementation to practice? AM Berger, SA Mitchell, PB Jacobsen, WF Pirl CA: a cancer journal for clinicians 65 (3), 190-211, 2015 | 207 | 2015 |
| Cancer‐related fatigue and its impact on functioning O Minton, A Berger, A Barsevick, F Cramp, M Goedendorp, SA Mitchell, ... Cancer 119, 2124-2130, 2013 | 200 | 2013 |
| International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium C Coens, M Pe, AC Dueck, J Sloan, E Basch, M Calvert, A Campbell, ... The Lancet Oncology 21 (2), e83-e96, 2020 | 198 | 2020 |
| Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards A Bottomley, M Pe, J Sloan, E Basch, F Bonnetain, M Calvert, A Campbell, ... The Lancet Oncology 17 (11), e510-e514, 2016 | 194 | 2016 |
| A thematic analysis of theoretical models for translational science in nursing: Mapping the field SA Mitchell, CA Fisher, CE Hastings, LB Silverman, GR Wallen Nursing outlook 58 (6), 287-300, 2010 | 187 | 2010 |
| Clinical activity of the γ-secretase inhibitor PF-03084014 in adults with desmoid tumors (aggressive fibromatosis) S Kummar, GOS Coyne, KT Do, B Turkbey, PS Meltzer, E Polley, ... Journal of Clinical Oncology 35 (14), 1561, 2017 | 158 | 2017 |
